Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Clinical Trial Compares Lymphoma Regimens
Clinical Breakthroughs

Clinical Trial Compares Lymphoma Regimens

By Sarah PlumridgeSep 22, 2015
Share
Facebook Twitter Email
Leo Gordon
Leo Gordon, MD, Abby and John Friend Professor of Oncology Research, conducted a phase III randomized clinical trial comparing two therapies for patients with advanced Hodgkin lymphoma.

With new treatments being developed for patients with advanced Hodgkin lymphoma, Leo Gordon, MD, Abby and John Friend Professor of Cancer Research, along with co-authors across North America, conducted a phase III randomized clinical trial to determine which drug regimens were superior.

In a recently published paper in the Journal of Clinical Oncology, they described the results from a subset of patients in an earlier clinical trial with stages I or II bulky mediastinal Hodgkin lymphoma. While they found no significant differences between two popular regimens in patients, this study was the first prospective trial reporting outcomes in this patient subgroup, and the authors noted it set a benchmark for future studies.

A previously published paper compared the regimens ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) and Stanford V and found no significant difference in the overall response rate, which the authors said confirmed that ABVD should remain the standard of care for patients with advanced Hodgkin lymphoma.

Both papers drew upon patients enrolled in one large multi-site clinical trial. Of the 854 patients enrolled from 1999 to 2006 in the original clinical trial, more than 260 of them were eligible for the most recent study, which focused on only patients with bulky mediastinal Hodgkin lymphoma.

“These papers together highlight translational research and demonstrate that many questions, other than the one originally intended, can be answered in a large clinical trial,” said Dr. Gordon, also professor of Hematology/Oncology in the Department of Medicine  and co-Director of the Hematologic Malignancies Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Dr. Gordon said that investigators were able to ask different questions about the smaller subset of patients, which allowed them to more precisely establish the most effective treatment for the disease. Other published findings that stemmed from the same trial included finding biomarkers to identify patients with a significantly increased risk of death and learning that the Epstein-Barr virus DNA in blood plasma predicted patient outcomes in advanced Hodgkin lymphoma.

“We are trying to get all the important questions on these patients answered, so we then can look at better treatments,” Dr. Gordon said.

The study was funded in part by Public Health Service Grants No. CA21115, CA23318, CA66636, CA17145, CA77440, CA11083, CA32102, CA46441, CA46282, CA38926, CA77202, CA21076, CA31946 and CA13650 from the National Cancer Institute, National Institutes of Health and Department of Health and Human Services.

If you are interested in participating in research at Northwestern University, please call the NU Study line at 1-855-NU-STUDY. Or get connected by visiting http://bit.ly/NUStudy to sign up for Northwestern’s Research Registry.

Cancer Research
Share. Facebook Twitter Email

Related Posts

Drug Extends Survival in Prostate Cancer with Genetic Mutations  

Dec 6, 2023

Pioneering Biochemist Craig Crews Named Winner of 2024 Kimberly Prize

Dec 5, 2023

Family Language Tied to Hospitalization Rates in Feverish Babies

Dec 5, 2023

Comments are closed.

Latest News

Drug Extends Survival in Prostate Cancer with Genetic Mutations  

Dec 6, 2023

Pioneering Biochemist Craig Crews Named Winner of 2024 Kimberly Prize

Dec 5, 2023

Family Language Tied to Hospitalization Rates in Feverish Babies

Dec 5, 2023

New Therapeutic Strategies for Spinal Muscular Atrophy

Dec 4, 2023

Investigating Drug Combinations for Heart Failure

Dec 1, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
2023-Sim-Open-House_161
2023-Sim-Open-House_127
2023-Sim-Open-House_108
2023-Sim-Open-House_106
2023-Sim-Open-House_118
2023-Sim-Open-House_068
2023-Sim-Open-House_069
2023-Sim-Open-House_027
2023-Sim-Open-House_155
2023-Sim-Open-House_161
2023-Sim-Open-House_127
2023-Sim-Open-House_108

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.